Which adverse reactions are patients homozygous for the UGT1A1*28 allele at increased risk of during sacituzumab govitecan treatment?

Patients homozygous for the UGT1A1*28 allele have an increased risk of severe neutropenia, severe diarrhoea, febrile neutropenia, anaemia and other adverse reactions following initiation of sacituzumab govitecan (Trodelvy) treatment.